Revelation Biosciences, Inc.
REVB
$2.72
$0.145.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.39% | 4.36% | -9.28% | -14.27% | 10.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.43% | 10.14% | -24.59% | -35.32% | 30.49% |
| Operating Income | 2.43% | -10.14% | 24.59% | 35.32% | -30.49% |
| Income Before Tax | 70.86% | 23.51% | 21.66% | 14.72% | -479.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.86% | 23.51% | 21.66% | 14.72% | -479.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.86% | 23.51% | 21.66% | 14.72% | -479.33% |
| EBIT | 2.43% | -10.14% | 24.59% | 35.32% | -30.49% |
| EBITDA | 2.43% | -10.12% | 24.70% | 35.43% | -30.54% |
| EPS Basic | 97.15% | 94.64% | -- | -- | -- |
| Normalized Basic EPS | 98.76% | 94.64% | -- | -- | -- |
| EPS Diluted | 97.15% | 94.64% | -- | -- | -- |
| Normalized Diluted EPS | 98.76% | 94.64% | -- | -- | -- |
| Average Basic Shares Outstanding | 2,253.96% | 1,326.43% | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,253.96% | 1,326.43% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |